The Use of BRILInta to Optimize ANTiplatelet Therapy (BRILIANT) Registry: The BRILIANT KOREA Registry

Trial Profile

The Use of BRILInta to Optimize ANTiplatelet Therapy (BRILIANT) Registry: The BRILIANT KOREA Registry

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2015

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Acute coronary syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BK Registry; BRILIANT; BRILIANT KOREA
  • Most Recent Events

    • 18 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top